Clinical trial
PR-104 in Treating Patients With Advanced Solid Tumors
NCT00349167 · Proacta, Incorporated, Industry · Completed
Key facts
| NCT number | NCT00349167 |
|---|---|
| Title | PR-104 in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I, Multi-Center, Open Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Every 3 Weeks in Patients With Solid Tumors |
| Lead sponsor | Proacta, Incorporated, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | PR-104, laboratory biomarker analysis, pharmacological study |
| Enrollment | 27 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jul 6, 2006 |
| Last update posted | Nov 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: